Chronic oxidative stress and inflammation are central to the pathogenesis of CKM, and these processes are further intensified in cancer patients undergoing aggressive therapies; sGC activators counteract oxidative stress by promoting the production of cGMP, which, in turn, activates the cGMP-dependent protein kinase (PKG). Here, CKM is linked to cancer.